Mexico Blood Testing Market Size & Outlook, 2025-2033
Mexico Blood Testing Market Insights
- Based on Reed Intelligence findings, the Mexico Blood Testing Market reached USD 2103.73 Million in 2024 and is estimated to attain USD 4002.76 Million by 2033.
- From 2026 to 2033, the Mexico market is expected to grow at a steady CAGR of 7.34%.
- Within the By Offerings category, Solutions dominated in 2024 in terms of market size contribution.
- Over the forecast period, Solutions is forecasted to deliver the fastest growth, positioning it as the most lucrative By Offerings segment.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- Mexico accounted for 2.24% of the global Blood Testing Market size in 2024.
- By 2033, United States is expected to remain the top global market in terms of size.
- Within LATAM, Brazil is forecasted to dominate the regional Blood Testing Market size by 2033.
- Colombia will be the fastest-growing market in LATAM, projected to achieve USD 1024.93 Million by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 2103.73 Million |
| Market Size In 2033 | USD 4002.76 Million |
| Largest segment | Solutions |
| Units | Revenue in USD Million |
| CAGR | 7.34% (2025-2033) |
| Segmnetation Covered | |
| By Offerings |
|
| By Test Type |
|
| By Method |
|
| By End-Use |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Mexico Blood Testing Market By Offerings 2025-2033 (USD Million)
| By Offerings | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Solutions | XX.x | XX.x | XX.x | 1277.81 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Software | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Mexico Blood Testing Market By Test Type 2025-2033 (USD Million)
| By Test Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glucose Testing | XX.x | XX.x | XX.x | 672.98 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Lipid Panel Testing | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Prostate Specific Antigen (PSA) Testing | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Blood Urea Nitrogen (BUN) Testing | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Thyroid Stimulating Hormone Testing | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Mexico Blood Testing Market By Method 2025-2033 (USD Million)
| By Method | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Automated | XX.x | XX.x | XX.x | 1237.83 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Manual | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Mexico Blood Testing Market By End-Use 2025-2033 (USD Million)
| By End-Use | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospitals & Clinics | XX.x | XX.x | XX.x | 860.22 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Diagnostic Centers | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Remote Testing | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
